Improving Genetic Counseling for BRCA+ Mothers
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Georgetown University
- Study ID
- NCT04258280
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Education and counseling — BEHAVIORALEducation includes a workbook, counseling includes peer support.
- Education — BEHAVIORALEducation includes a workbook.
Study Details
Genetic counseling and testing for hereditary breast cancer may reveal that you, and possibly your blood relatives, are at increased risk for the disease across the lifespan. This includes biological children, both male and female. We do not yet know the best ways to educate mothers who have a risk gene (are BRCA+) about whether, when, and how to share genetic information with their children or manage their thoughts and feelings. The purpose of this study is to help mothers make more informed choices about talking with children about hereditary breast cancer, provide them with age-and gender-appropriate information and emotional support, and improve their psychological well-being.
Key Dates
- Start date
- Jul 1, 2020
- Status verified
- Sep 2024
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Active Comparator: Usual Care
- Experimental: Enhanced Care
Primary Outcome Measure
Communication [ Time Frame: 1- and 6-months post-treatment ]
Central Contacts
- Kenneth Tercyak, PhD202-687-0802
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | Principal Investigator |
Find similar trials in Washington D.C., DC
Related Studies
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPHASE3 · Recruiting · Canadian Cancer Trials Group · Fairbanks, Alaska
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerPHASE2 · Recruiting · Abramson Cancer Center at Penn Medicine · Washington D.C., District of Columbia
- Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsPHASE3 · Recruiting · Greenwich LifeSciences, Inc. · Mobile, Alabama